Details for New Drug Application (NDA): 050182
✉ Email this page to a colleague
NDA 050182 describes ERYTHROCIN, which is a drug marketed by Abbott, Hospira, and Azurity, and is included in five NDAs. It is available from one supplier. Additional details are available on the ERYTHROCIN profile page.
The generic ingredient in ERYTHROCIN is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
The generic ingredient in ERYTHROCIN is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
Summary for 050182
| Tradename: | ERYTHROCIN |
| Applicant: | Hospira |
| Ingredient: | erythromycin lactobionate |
| Patents: | 0 |
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 500MG BASE/VIAL | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/VIAL | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
